Related Experiment Video
Updated: Jun 8, 2026
Minimally Invasive Treatment for Thoracolumbar Burst Fracture Using Sagittal Alignment Screws and A Trauma Reduction Device
Published on: November 8, 2024
Short-term treatment with COX-2 inhibitors does not impair fracture healing
Stein Erik Utvåg1, Ole Martin Fuskevåg, Hamid Shegarfi
1Department of Orthopaedics, Akershus University Hospital, University of Oslo, Oslo, Norway.
Background:
The effects of cyclooxygenase (COX) inhibition on fracture healing are insufficiently documented, and the aim of this study was to evaluate the effects of nonspecific and specific COX-2 inhibition in the early phase of fracture healing.
Methods:
Thirty rats were randomized in three groups. A diaphyseal fracture was performed and stabilized by intramedullary nailing. In group A parecoxib in a dose of 1 mg/kg body weight/day was given prior to surgery and daily for seven days; in group B diclofenac 2 mg/kg body weight/day was given; and in group C the same amount of saline was given. Blood samples were harvested at 7 and 30 days postoperatively and analyzed for active medications. At 30 days the rats were sacrificed, and the fractures were examined for bone mineralization and tested mechanically.
Results:
The fractures healed by the production of callus. Plasma concentrations at seven days of medication revealed therapeutic levels of parecoxib, valdecoxib, and diclofenac. There were no significant differences in bone mineralization or mechanical characteristics between the three groups at 30 days postfracture.
Conclusion:
This study indicates that nonspecific or specific COX-2 inhibitors in therapeutic doses during seven days after fracture do not significantly influence bone healing.
Related Concept Videos
01:27Fractures: Bone Repair
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the procedure...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...